세계의 안전 란셋 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of safety lancets Market

The global safety lancets market continues to expand rapidly as healthcare systems emphasize safer blood sampling and diabetes management solutions. According to the latest industry assessment, the safety lancets market size reached USD 1.09 billion in 2024. The market is projected to grow further to USD 1.21 billion in 2025 and nearly double to USD 2.60 billion by 2032, exhibiting a strong CAGR of 11.5% during the forecast period. This sustained growth stems from rising diabetes prevalence, expansion in home healthcare, and increasing regulatory focus on safe needle practices across clinical and non-clinical settings.

North America held the largest regional share of 37.61% in 2024, reflecting high disease burden, strong reimbursement support, and strong penetration of advanced safety lancet products. The U.S. market benefits significantly from Medicare coverage, which reimburses up to 300 lancets every 3 months for insulin-dependent diabetic patients under Medicare Part B, driving consistent demand.

Growing Chronic Disease Burden Driving Market Expansion

The global rise in diabetes remains the primary driver for the adoption of safety lancets. According to the Institute for Health Metrics and Evaluation (2023), over 500 million individuals worldwide live with diabetes. This surge has elevated the need for accurate and frequent blood glucose monitoring, significantly boosting the usage of safety lancets for capillary blood collection. These devices provide needle-stick protection, ensure safer handling, and reduce infection risks for both patients and healthcare providers.

The trend toward self-monitoring of blood glucose (SMBG) also supports the market, with patients increasingly preferring safe, easy-to-use lancets for home testing. In India, for example, a 2023 study published in the Indian Journal of Medical Specialties found that 35% of patients performed home glucose monitoring, highlighting the transition toward decentralized care.

Cost Barriers Limit Adoption in Low-Income Markets

Despite their clinical advantages, safety lancets face adoption challenges in cost-sensitive regions. Safety-engineered lancets are priced higher than traditional lancets, and the difference remains a barrier. In the U.K., NHS data from 2020 shows safety lancets can cost USD 4.87-5.06 per 100 units, whereas standard lancets cost USD 2.37-4.22 per 100 units. In developing markets, limited healthcare spending and low device reimbursement restrict widespread use, slowing market penetration.

Rising Home Healthcare Demand Creates Significant Opportunities

The shift toward home-based diagnostics is unlocking new growth avenues. Home-users require simple, painless, and safe blood sampling tools, making safety lancets a preferred choice. Many governments are pushing for at-home chronic disease management to reduce hospital burden, further elevating demand. Growing availability of home HbA1c kits and cholesterol testing devices, all requiring lancets, also supports market expansion.

Segmentation Overview

By Type

• Button-activated safety lancets led the market in 2024, driven by ease of use and strong adoption in clinical settings.
• Pressure/contact-activated lancets are expanding rapidly, offering consistent puncture depth and lower risk of accidental exposure.

By Incision Type

• Needle lancets dominated in 2024, preferred for lower pain, enhanced safety, and suitability for frequent testing.
• Blade lancets are gaining traction for neonatal screening and dried blood spot (DBS) tests due to their higher blood yield.

By Age Group

• Adults accounted for the largest share in 2024, attributed to high testing volumes for HbA1c, cholesterol, and blood glucose.
• Pediatrics is the fastest-growing segment due to daily testing needs in Type 1 diabetes.

By Application

• Blood glucose monitoring remained the largest segment in 2024, driven by the rising global diabetes burden.
• Hemoglobin testing, cholesterol profiling, and DBS testing also contribute significantly to demand.

Regional Outlook

North America (USD 0.41 Billion in 2024)

Dominates due to high diabetes prevalence, Medicare coverage, and strong manufacturer presence.

Europe

Strong adoption driven by advanced healthcare systems. NHS England and Wales spent USD 13.42 million on safety lancets in 2020.

Asia Pacific

Fastest-growing region, propelled by large diabetic populations in China and India, and expanding domestic manufacturing.

Latin America

Growth supported by rising diabetes cases and expanding home monitoring adoption.

Middle East & Africa

Gradual expansion driven by government focus on non-communicable diseases.

Competitive Landscape

Key market players include BD, HTL-STREFA, Abbott, SARSTEDT AG & Co. KG, Terumo Medical Corporation, Cardinal Health, B. Braun, Ypsomed, and others. Companies are focusing on product innovation, portfolio expansion, and strategic partnerships to strengthen global market presence.

Segmentation By Type

• Button-activated
• Pressure/Contact-activated

By Incision Type

• Needle
• Blade

By Age Group

• Adult
• Pediatric

By Application

• Blood Glucose Monitoring
• Hemoglobin Testing
• Cholesterol Testing
• Others

By End-user

• Hospitals & Clinics
• Home Care
• Others

By Region

• North America (By Type, Incision Type, Age Group, Application, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Type, By Incision Type, Age Group, Application, End-user, and Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, By Incision Type, Age Group, Application, End-user, and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, By Incision Type, Age Group, Application, End-user, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, By Incision Type, Age Group, Application, End-user, and Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries/Region, 2024
• 4.2. Number of SMBG User, By Key Countries/Region, 2024
• 4.3. Advancements in Safety Lancets
• 4.4. Overview: Reimbursement Scenario
• 4.5. Key Industry Developments - (Mergers, Acquisition & Partnerships, etc.)

5. Global Safety Lancets Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Button-activated
  • 5.1.2. Pressure/Contact-activated
• 5.2. Market Analysis, Insights and Forecast - By Incision Type
  • 5.2.1. Needle
  • 5.2.2. Blade
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Adult
  • 5.3.2. Pediatric
• 5.4. Market Analysis, Insights and Forecast - By Application
  • 5.4.1. Blood Glucose Monitoring
  • 5.4.2. Hemoglobin Testing
  • 5.4.3. Cholesterol Testing
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By End-user
  • 5.5.1. Hospitals & Clinics
  • 5.5.2. Home Care
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Safety Lancets Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Button-activated
  • 6.1.2. Pressure/Contact-activated
• 6.2. Market Analysis, Insights and Forecast - By Incision Type
  • 6.2.1. Needle
  • 6.2.2. Blade
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Adult
  • 6.3.2. Pediatric
• 6.4. Market Analysis, Insights and Forecast - By Application
  • 6.4.1. Blood Glucose Monitoring
  • 6.4.2. Hemoglobin Testing
  • 6.4.3. Cholesterol Testing
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By End-user
  • 6.5.1. Hospitals & Clinics
  • 6.5.2. Home Care
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Safety Lancets Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Button-activated
  • 7.1.2. Pressure/Contact-activated
• 7.2. Market Analysis, Insights and Forecast - By Incision Type
  • 7.2.1. Needle
  • 7.2.2. Blade
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Adult
  • 7.3.2. Pediatric
• 7.4. Market Analysis, Insights and Forecast - By Application
  • 7.4.1. Blood Glucose Monitoring
  • 7.4.2. Hemoglobin Testing
  • 7.4.3. Cholesterol Testing
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By End-user
  • 7.5.1. Hospitals & Clinics
  • 7.5.2. Home Care
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. Germany
  • 7.6.2. U.K.
  • 7.6.3. France
  • 7.6.4. Italy
  • 7.6.5. Spain
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia pacific Safety Lancets Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Button-activated
  • 8.1.2. Pressure/Contact-activated
• 8.2. Market Analysis, Insights and Forecast - By Incision Type
  • 8.2.1. Needle
  • 8.2.2. Blade
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Adult
  • 8.3.2. Pediatric
• 8.4. Market Analysis, Insights and Forecast - By Application
  • 8.4.1. Blood Glucose Monitoring
  • 8.4.2. Hemoglobin Testing
  • 8.4.3. Cholesterol Testing
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By End-user
  • 8.5.1. Hospitals & Clinics
  • 8.5.2. Home Care
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Safety Lancets Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Button-activated
  • 9.1.2. Pressure/Contact-activated
• 9.2. Market Analysis, Insights and Forecast - By Incision Type
  • 9.2.1. Needle
  • 9.2.2. Blade
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Adult
  • 9.3.2. Pediatric
• 9.4. Market Analysis, Insights and Forecast - By Application
  • 9.4.1. Blood Glucose Monitoring
  • 9.4.2. Hemoglobin Testing
  • 9.4.3. Cholesterol Testing
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By End-user
  • 9.5.1. Hospitals & Clinics
  • 9.5.2. Home Care
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Safety Lancets Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Button-activated
  • 10.1.2. Pressure/Contact-activated
• 10.2. Market Analysis, Insights and Forecast - By Incision Type
  • 10.2.1. Needle
  • 10.2.2. Blade
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Adult
  • 10.3.2. Pediatric
• 10.4. Market Analysis, Insights and Forecast - By Application
  • 10.4.1. Blood Glucose Monitoring
  • 10.4.2. Hemoglobin Testing
  • 10.4.3. Cholesterol Testing
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By End-user
  • 10.5.1. Hospitals & Clinics
  • 10.5.2. Home Care
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. BD
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. SARSTEDT AG & Co. KG
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Greiner Bio-One International GmbH
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. HTL-STREFA (MTD Medical Technology and Devices)
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Terumo Medical Corporation
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. B. Braun SE
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Abbott
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Cardinal Health
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. YPSOMED
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Biosense Technologies Private Limited
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)